Patents by Inventor John Emtage

John Emtage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanised antibodies
    Publication number: 20060073137
    Abstract: CDR-grafted antibody heavy and light chain comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71), The CDR-grafted antibodies are preferably humanised antibodies, having non human, eg. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generall applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Application
    Filed: November 21, 2005
    Publication date: April 6, 2006
    Applicant: Celltech R&D Limited
    Inventors: John Adair, Diljeet Athwal, John Emtage
  • Humanised antibodies
    Publication number: 20060073136
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Application
    Filed: November 21, 2005
    Publication date: April 6, 2006
    Applicant: Celltech R&D Limited
    Inventors: John Adair, Diljeet Athwal, John Emtage
  • Humanised antibodies
    Publication number: 20060029593
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46,48, 58) and (71). The CDR-grafted antibodies arc preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis.
    Type: Application
    Filed: September 10, 2004
    Publication date: February 9, 2006
    Applicant: Celltech R&D Limited
    Inventors: John Adair, Diljeet Athwal, John Emtage
  • Humanised antibodies
    Publication number: 20050202529
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, eg. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Application
    Filed: November 7, 2003
    Publication date: September 15, 2005
    Inventors: John Adair, Diljeet Athwal, John Emtage
  • Humanised antibodies
    Publication number: 20050136054
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Application
    Filed: September 10, 2004
    Publication date: June 23, 2005
    Applicant: Celltech R&D Limited
    Inventors: John Adair, Diljeet Athwal, John Emtage
  • Humanised antibodies
    Publication number: 20050123534
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46,48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Application
    Filed: September 10, 2004
    Publication date: June 9, 2005
    Applicant: Celltech R&D Limited
    Inventors: John Adair, Diljeet Athwal, John Emtage